Matrifen (Fentanyl)

• Fentanyl, delivered via a transdermal system, is used for managing severe pain conditions that are unresponsive to less potent analgesics.
• Severe chronic non‑cancer pain: provides continuous opioid analgesia for patients requiring around‑the‑clock pain control.
• Cancer‑related pain: alleviates moderate to severe pain associated with malignancies and cancer treatments.
• Post‑surgical pain (when oral opioids are unsuitable): offers sustained analgesia during recovery.
• Breakthrough cancer pain episodes: can be supplemented with short‑acting opioids for rapid relief while the patch maintains baseline control.

• Fentanyl is a high‑affinity agonist at the µ‑opioid receptors in the central nervous system. By binding to these G‑protein‑coupled receptors, it inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and suppression of pain signal transmission. The transdermal matrix allows fentanyl to be absorbed steadily through the skin, achieving stable plasma concentrations over several days.

Fentanyl transdermal therapy can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Skin irritation at application site: redness, itching or rash.
• Nausea or vomiting: mild gastrointestinal upset.
• Constipation: reduced bowel motility.
• Drowsiness or sedation: feeling unusually sleepy.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing, potentially life‑threatening.
• Hypotension or bradycardia: marked drop in blood pressure or heart rate.
• Severe allergic reaction: anaphylaxis with hives, swelling, or airway compromise.

When prescribing or handling fentanyl patches, clinicians and patients should observe several safety measures to minimize risk.

• Dose titration: adjust strength based on individual opioid tolerance and clinical response.
• Respiratory monitoring: assess breathing regularly, especially during initiation or dose changes.
• Concomitant CNS depressants: avoid or use with caution when combined with benzodiazepines, alcohol, or other sedatives.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Disposal: follow local regulations for controlled substances to prevent accidental exposure.
• Store at room temperature: keep patches below 25 °C in the original packaging, protected from moisture and direct sunlight.

Fentanyl may interact with several medicines; clinicians should review a patient’s full medication list.

Major Interactions (Avoid)

• Other opioids or strong CNS depressants: may cause profound respiratory depression and sedation.
• MAO inhibitors: risk of severe opioid toxicity, including respiratory failure.
• Cytochrome P450 3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase fentanyl plasma levels, leading to overdose.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fentanyl concentrations, decreasing analgesic effect.
• Serotonergic agents (e.g., SSRIs, tramadol): potential for serotonin syndrome, monitor for symptoms.
• Diuretics: may enhance hypotensive effects, observe blood pressure.